乾癬藥物市場規模、佔有率、趨勢分析報告：按類別、治療、給藥途徑、分銷管道、地區、細分市場預測，2025-2030 年

Psoriasis Drugs Market Size, Share & Trends Analysis Report By Class, By Treatment (Topicals, Systemic, Biologics), By Route Of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

出版日期: 2025年05月16日 | 出版商:

Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

乾癬藥物市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球乾癬藥物市場規模預計到2030年將達到391.1億美元，預計2025年至2030年期間的複合年成長率為10.94%。

人們對該疾病的認知不斷提高、生物製藥報銷策略的增加以及先進的診斷和技術工具可能會增加乾癬藥物的採用。

此外，不斷擴大的乾癬患者群體預計將推動其成長前景。乾癬的確切致病因素尚待確定，但某些遺傳和環境因素可能誘發其發病。大多數現有治療方法旨在透過抑制角質形成細胞的過度增殖來減緩疾病的進展。

乾癬分為五種類型：斑塊、斑塊狀、逆性、膿皰型、紅皮症型。這些類型根據病變部位和特徵而有所不同。紅皮病乾癬最為罕見，而斑塊乾癬則是全球最常見的乾癬類型。

近年來，乾癬的盛行率在各地區呈現逐漸上升趨勢。這種上升可能源自於遺傳、環境因素以及生活方式的改變。盛行率的上升也可能與患者對疾病控制治療的反應性降低和抗藥性發展有關。

乾癬藥物市場報告重點

腫瘤壞死因子抑制劑將佔據市場主導地位，到 2024 年將佔 40.88% 的佔有率。
生物製藥領域在 2024 年佔據了 46.38% 的市場佔有率，這得益於其對與乾癬相關的特定免疫途徑的高度選擇性，與傳統藥物相比，其疾病控制效果顯著改善。
預計在預測期內局部用藥領域將實現顯著的成長率。
腸外藥物領域將佔據市場主導地位，到 2024 年將佔 41.58% 的佔有率。
到 2024 年，醫院藥房部門將佔據乾癬藥物行業的主要佔有率。
2024年北美乾癬藥物市場佔據主導地位，佔全球佔有率的38.65%。

2025年及2030年區域市場佔有率分析
區域市場儀表板
2018-2030年市場規模及預測趨勢分析
北美洲
- 2018-2030年各國情況
- 美國
- 加拿大
- 墨西哥
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 丹麥
- 瑞典
- 挪威
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 泰國
拉丁美洲
- 巴西
- 阿根廷
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 科威特

第9章競爭態勢

參與者概覽
企業市場分析
公司分類
戰略地圖
公司簡介/上市公司
- AbbVie Inc.
- Amgen Inc.
- Johnson &Johnson Services, Inc.
- Novartis AG
- Eli Lilly and Company
- AstraZeneca
- Celgene Corporation
- UCB SA
- Merck
- Boehringer Ingelheim International GmbH

簡介目錄圖表

Product Code: GVR-1-68038-662-2

Psoriasis Drugs Market Growth & Trends:

The global psoriasis drugs market size is estimated to reach USD 39.11 billion by 2030, registering to grow at a CAGR of 10.94% from 2025 to 2030 according to a new report by Grand View Research, Inc. Rising disease awareness, an increasing number of reimbursement strategies for biologics, and advanced diagnostic and technological tools are likely to increase the adoption of psoriasis therapeutics.

Additionally, the expanding base of patients suffering from psoriasis is anticipated to fuel growth prospects. The exact causative factors for psoriasis are undetermined; however, certain genetic and environmental factors may trigger the disease onset. Most available treatments aim to decelerate disease progression by stopping the hyperproliferation of keratinocyte.

Psoriasis can be classified into five types: plaque, guttate, inverse, pustular, and erythrodermic. The types vary in terms of the site of disease and characterization of lesions. Erythrodermic psoriasis is the rarest and plaque psoriasis is the most prevalent type affecting patients all over the world.

The incidence rate of psoriasis has witnessed a gradual rise over the years across various geographical locations. This increase can be attributed to genetic and environmental triggers as well as lifestyle changes. The rise in prevalence rates could also be associated with declining response or developing resistance to therapies for disease control.

Psoriasis Drugs Market Report Highlights:

Tumor necrosis factor inhibitors dominated the market and accounted for a share of 40.88% in 2024 as they effectively target the inflammatory pathways crucial to the disease, resulting in major enhancements.
The biologics segment dominated the market in 2024 with a share of 46.38% as they are highly selective to certain immune pathways in connection to psoriasis and massive improvements in disease management compared to traditional medicines.
The topical segment is expected to register a significant growth rate over the forecast period.
The parenteral segment dominated the market, accounting for a 41.58% share in 2024.
The hospital pharmacies segment accounted for a leading share of the psoriasis drugs industry in 2024.
North America psoriasis drugs market held a leading market position in 2024, accounting for 38.65% of the global share.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Class
- 1.2.2. Treatment
- 1.2.3. Route of Administration
- 1.2.4. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Psoriasis Drug Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis

Chapter 4. Psoriasis Drug Market: Class Business Analysis

4.1. Class Market Share, 2025 & 2030
4.2. Class Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Class, 2018 to 2030 (USD Million)
4.4. Tumor Necrosos Factor Inhibitors
- 4.4.1. Tumor Necrosos Factor Inhibitors Market, 2018 - 2030 (USD Million)
4.5. Interleukin Inhibitors
- 4.5.1. Interleukin Inhibitors Market, 2018 - 2030 (USD Million)
4.6. Vitamin D Analogues
- 4.6.1. Vitamin D Analogues Market, 2018 - 2030 (USD Million)
4.7. Corticosteroids
- 4.7.1. Corticosteroids Market, 2018 - 2030 (USD Million)
4.8. Others
- 4.8.1. Other Class Market, 2018 - 2030 (USD Million)

Chapter 5. Psoriasis Drug Market: Treatment Business Analysis

5.1. Treatment Market Share, 2025 & 2030
5.2. Treatment Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
5.4. Topicals
- 5.4.1. Topicals Market, 2018 - 2030 (USD Million)
5.5. Systemic
- 5.5.1. Systemic Market, 2018 - 2030 (USD Million)
5.6. Biologics
- 5.6.1. Biologics Market, 2018 - 2030 (USD Million)

Chapter 6. Psoriasis Drug Market: Route of Administration Business Analysis

6.1. Route of Administration Market Share, 2025 & 2030
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
6.4. Oral
- 6.4.1. Oral Market, 2018 - 2030 (USD Million)
6.5. Parental
- 6.5.1. Parental Market, 2018 - 2030 (USD Million)
6.6. Topical
- 6.6.1. Tropical Market, 2018 - 2030 (USD Million)

Chapter 7. Psoriasis Drug Market: Distribution Channel Business Analysis

7.1. Distribution Channel Market Share, 2025 & 2030
7.2. Distribution Channel Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
7.4. Hospital Pharmacies
- 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
7.5. Retail Pharmacies
- 7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
7.6. Other Pharmacies
- 7.6.1. Others Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Psoriasis Drug Market: Regional Estimates & Trend Analysis

8.1. Regional Market Share Analysis, 2025 & 2030
8.2. Regional Market Dashboard
8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
8.4. North America
- 8.4.1. North America Psoriasis Drug Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 8.4.2. U.S.
  - 8.4.2.1. Key Country Dynamics
  - 8.4.2.2. Target Disease Prevalence
  - 8.4.2.3. Regulatory Framework
  - 8.4.2.4. Reimbursement Framework
  - 8.4.2.5. U.S. Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.3. Canada
  - 8.4.3.1. Key Country Dynamics
  - 8.4.3.2. Target Disease Prevalence
  - 8.4.3.3. Regulatory Framework
  - 8.4.3.4. Reimbursement Framework
  - 8.4.3.5. U.S. Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.4. Mexico
  - 8.4.4.1. Key Country Dynamics
  - 8.4.4.2. Target Disease Prevalence
  - 8.4.4.3. Regulatory Framework
  - 8.4.4.4. Reimbursement Framework
  - 8.4.4.5. Mexico Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Europe
- 8.5.1. Europe Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.2. UK
  - 8.5.2.1. Key Country Dynamics
  - 8.5.2.2. Target Disease Prevalence
  - 8.5.2.3. Regulatory Framework
  - 8.5.2.4. Reimbursement Framework
  - 8.5.2.5. Uk Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.3. Germany
  - 8.5.3.1. Key Country Dynamics
  - 8.5.3.2. Target Disease Prevalence
  - 8.5.3.3. Regulatory Framework
  - 8.5.3.4. Reimbursement Framework
  - 8.5.3.5. Germany Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.4. France
  - 8.5.4.1. Key Country Dynamics
  - 8.5.4.2. Target Disease Prevalence
  - 8.5.4.3. Regulatory Framework
  - 8.5.4.4. Reimbursement Framework
  - 8.5.4.5. France Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.5. Italy
  - 8.5.5.1. Key Country Dynamics
  - 8.5.5.2. Target Disease Prevalence
  - 8.5.5.3. Regulatory Framework
  - 8.5.5.4. Reimbursement Framework
  - 8.5.5.5. Italy Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.6. Spain
  - 8.5.6.1. Key Country Dynamics
  - 8.5.6.2. Target Disease Prevalence
  - 8.5.6.3. Regulatory Framework
  - 8.5.6.4. Reimbursement Framework
  - 8.5.6.5. Spain Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.7. Denmark
  - 8.5.7.1. Key Country Dynamics
  - 8.5.7.2. Target Disease Prevalence
  - 8.5.7.3. Regulatory Framework
  - 8.5.7.4. Reimbursement Framework
  - 8.5.7.5. Denmark Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.8. Sweden
  - 8.5.8.1. Key Country Dynamics
  - 8.5.8.2. Target Disease Prevalence
  - 8.5.8.3. Regulatory Framework
  - 8.5.8.4. Reimbursement Framework
  - 8.5.8.5. Sweden Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.9. Norway
  - 8.5.9.1. Key Country Dynamics
  - 8.5.9.2. Target Disease Prevalence
  - 8.5.9.3. Regulatory Framework
  - 8.5.9.4. Reimbursement Framework
  - 8.5.9.5. Norway Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Asia Pacific
- 8.6.1. Asia Pacific Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.2. Japan
  - 8.6.2.1. Key Country Dynamics
  - 8.6.2.2. Target Disease Prevalence
  - 8.6.2.3. Regulatory Framework
  - 8.6.2.4. Reimbursement Framework
  - 8.6.2.5. Japan Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.3. China
  - 8.6.3.1. Key Country Dynamics
  - 8.6.3.2. Target Disease Prevalence
  - 8.6.3.3. Regulatory Framework
  - 8.6.3.4. Reimbursement Framework
  - 8.6.3.5. China Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.4. India
  - 8.6.4.1. Key Country Dynamics
  - 8.6.4.2. Target Disease Prevalence
  - 8.6.4.3. Regulatory Framework
  - 8.6.4.4. Reimbursement Framework
  - 8.6.4.5. India Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.5. Australia
  - 8.6.5.1. Key Country Dynamics
  - 8.6.5.2. Target Disease Prevalence
  - 8.6.5.3. Regulatory Framework
  - 8.6.5.4. Reimbursement Framework
  - 8.6.5.5. Australia Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.6. South Korea
  - 8.6.6.1. Key Country Dynamics
  - 8.6.6.2. Target Disease Prevalence
  - 8.6.6.3. Regulatory Framework
  - 8.6.6.4. Reimbursement Framework
  - 8.6.6.5. South Korea Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.7. Thailand
  - 8.6.7.1. Key Country Dynamics
  - 8.6.7.2. Target Disease Prevalence
  - 8.6.7.3. Regulatory Framework
  - 8.6.7.4. Reimbursement Framework
  - 8.6.7.5. Thailand Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.7. Latin America
- 8.7.1. Latin America Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7.2. Brazil
  - 8.7.2.1. Key Country Dynamics
  - 8.7.2.2. Target Disease Prevalence
  - 8.7.2.3. Regulatory Framework
  - 8.7.2.4. Reimbursement Framework
  - 8.7.2.5. Japan Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7.3. Argentina
  - 8.7.3.1. Key Country Dynamics
  - 8.7.3.2. Target Disease Prevalence
  - 8.7.3.3. Regulatory Framework
  - 8.7.3.4. Reimbursement Framework
  - 8.7.3.5. China Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.8. Middle East and Africa
- 8.8.1. Middle East and Africa Psoriasis Drug Market Estimates and Forecasts, 2017 - 2030 (USD Million)
- 8.8.2. South Africa
  - 8.8.2.1. Key Country Dynamics
  - 8.8.2.2. Target Disease Prevalence
  - 8.8.2.3. Regulatory Framework
  - 8.8.2.4. Reimbursement Framework
  - 8.8.2.5. South Africa Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.3. Saudi Arabia
  - 8.8.3.1. Key Country Dynamics
  - 8.8.3.2. Target Disease Prevalence
  - 8.8.3.3. Regulatory Framework
  - 8.8.3.4. Reimbursement Framework
  - 8.8.3.5. Saudi Arabia Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.4. UAE
  - 8.8.4.1. Key Country Dynamics
  - 8.8.4.2. Target Disease Prevalence
  - 8.8.4.3. Regulatory Framework
  - 8.8.4.4. Reimbursement Framework
  - 8.8.4.5. UAE Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.5. Kuwait
  - 8.8.5.1. Key Country Dynamics
  - 8.8.5.2. Target Disease Prevalence
  - 8.8.5.3. Regulatory Framework
  - 8.8.5.4. Reimbursement Framework
  - 8.8.5.5. Kuwait Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
- 9.5.1. AbbVie Inc.
  - 9.5.1.1. Overview
  - 9.5.1.2. Financial Performance
  - 9.5.1.3. Product Benchmarking
  - 9.5.1.4. Strategic Initiatives
- 9.5.2. Amgen Inc.
  - 9.5.2.1. Overview
  - 9.5.2.2. Financial Performance
  - 9.5.2.3. Product Benchmarking
  - 9.5.2.4. Strategic Initiatives
- 9.5.3. Johnson & Johnson Services, Inc.
  - 9.5.3.1. Overview
  - 9.5.3.2. Financial Performance
  - 9.5.3.3. Product Benchmarking
  - 9.5.3.4. Strategic Initiatives
- 9.5.4. Novartis AG
  - 9.5.4.1. Overview
  - 9.5.4.2. Financial Performance
  - 9.5.4.3. Product Benchmarking
  - 9.5.4.4. Strategic Initiatives
- 9.5.5. Eli Lilly and Company
  - 9.5.5.1. Overview
  - 9.5.5.2. Financial Performance
  - 9.5.5.3. Product Benchmarking
  - 9.5.5.4. Strategic Initiatives
- 9.5.6. AstraZeneca
  - 9.5.6.1. Overview
  - 9.5.6.2. Financial Performance
  - 9.5.6.3. Product Benchmarking
  - 9.5.6.4. Strategic Initiatives
- 9.5.7. Celgene Corporation
  - 9.5.7.1. Overview
  - 9.5.7.2. Financial Performance
  - 9.5.7.3. Product Benchmarking
  - 9.5.7.4. Strategic Initiatives
- 9.5.8. UCB S.A.
  - 9.5.8.1. Overview
  - 9.5.8.2. Financial Performance
  - 9.5.8.3. Product Benchmarking
  - 9.5.8.4. Strategic Initiatives
- 9.5.9. Merck
  - 9.5.9.1. Overview
  - 9.5.9.2. Financial Performance
  - 9.5.9.3. Product Benchmarking
  - 9.5.9.4. Strategic Initiatives
- 9.5.10. Boehringer Ingelheim International GmbH
  - 9.5.10.1. Overview
  - 9.5.10.2. Financial Performance
  - 9.5.10.3. Product Benchmarking
  - 9.5.10.4. Strategic Initiatives

簡介目錄圖表

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global Psoriasis market, by region, 2018 - 2030 (USD Million)
Table 4 Global Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 5 Global Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 6 Global Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 7 Global Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 8 North America Psoriasis market, by country, 2018 - 2030 (USD Million)
Table 9 North America Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 10 North America Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 11 North America Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 12 North America Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 13 U.S. Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 14 U.S. Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 15 U.S. Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 16 U.S. Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 17 Canada Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 18 Canada Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 19 Canada Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 20 Canada Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 21 Mexico Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 22 Mexico Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 23 Mexico Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 24 Mexico Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 25 Europe Psoriasis market, by country, 2018 - 2030 (USD Million)
Table 26 Europe Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 27 Europe Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 28 Europe Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 29 Europe Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 30 UK Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 31 UK Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 32 UK Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 33 UK Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 34 Germany Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 35 Germany Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 36 Germany Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 37 Germany Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 38 France Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 39 France Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 40 France Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 41 France Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 42 Italy Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 43 Italy Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 44 Italy Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 45 Italy Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 46 Spain Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 47 Spain Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 48 Spain Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 49 Spain Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 50 Norway Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 51 Norway Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 52 Norway Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 53 Norway Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 54 Denmark Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 55 Denmark Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 56 Denmark Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 57 Denmark Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 58 Sweden Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 59 Sweden Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 60 Sweden Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 61 Sweden Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 62 Asia Pacific Psoriasis market, by country, 2018 - 2030 (USD Million)
Table 63 Asia Pacific Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 64 Asia Pacific Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 65 Asia Pacific Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 66 Asia Pacific Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 67 Japan Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 68 Japan Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 69 Japan Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 70 Japan Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 71 China Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 72 China Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 73 China Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 74 China Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 75 India Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 76 India Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 77 India Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 78 India Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 79 Australia Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 80 Australia Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 81 Australia Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 82 Australia Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 83 South Korea Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 84 South Korea Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 85 South Korea Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 86 South Korea Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 87 Thailand Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 88 Thailand Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 89 Thailand Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 90 Thailand Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 91 Latin America Psoriasis market, by country, 2018 - 2030 (USD Million)
Table 92 Latin America Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 93 Latin America Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 94 Latin America Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 95 Latin America Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 96 Brazil Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 97 Brazil Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 98 Brazil Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 99 Brazil Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 100 Argentina Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 101 Argentina Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 102 Argentina Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 103 Argentina Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 104 Middle East & Africa Psoriasis market, by country, 2018 - 2030 (USD Million)
Table 105 Middle East & Africa Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 106 Middle East & Africa Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 107 Middle East & Africa Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 108 Middle East & Africa Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 109 South Africa Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 110 South Africa Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 111 South Africa Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 112 South Africa Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 113 Saudi Arabia Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 114 Saudi Arabia Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 115 Saudi Arabia Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 116 Saudi Arabia Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 117 UAE Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 118 UAE Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 119 UAE Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 120 UAE Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
Table 121 Kuwait Psoriasis market, by class, 2018 - 2030 (USD Million)
Table 122 Kuwait Psoriasis market, by treatment, 2018 - 2030 (USD Million)
Table 123 Kuwait Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
Table 124 Kuwait Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)